Gene-to-Patient Market By Type-
Gene-to-Patient Market By Application-
Gene-to-Patient Market By End-user-
Gene-to-Patient Market By Technology-
Gene-to-Patient Market By Distribution Channel-
Gene-to-Patient Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene-to-Patient Market Snapshot
Chapter 4. Global Gene-to-Patient Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Gene-to-Patient Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Gene-to-Patient Industry Trends
Chapter 5. Gene-to-Patient Market Segmentation 1: By Application, Estimates & Trend Analysis
5.1. Market Share by Application, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
5.2.1. Cancer Treatment
5.2.2. Genetic Disorders
5.2.3. Cardiovascular Diseases
5.2.4. Rare Diseases
5.2.5. Infectious Diseases
Chapter 6. Gene-to-Patient Market Segmentation 2: By End-User, Estimates & Trend Analysis
6.1. Market Share by End-User, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User:
6.2.1. Hospitals
6.2.2. Research Institutes
6.2.3. Biopharmaceutical Companies
6.2.4. Diagnostic Laboratories
Chapter 7. Gene-to-Patient Market Segmentation 3: By Technology, Estimates & Trend Analysis
7.1. Market Share by Technology, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Technologys:
7.2.1. CRISPR
7.2.2. Viral Vector Technology
7.2.3. Non-Viral Delivery Technology
7.2.4. Antisense Oligonucleotide Technology
Chapter 8. Gene-to-Patient Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share by Type, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Types:
8.2.1. Gene Therapy
8.2.2. Gene Editing
8.2.3. Gene Silencing
Chapter 9. Gene-to-Patient Market Segmentation 5: By Distribution Channel, Estimates & Trend Analysis
9.1. Market Share by Distribution Channel, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channeles:
9.2.1. Direct Sales
9.2.2. Online Sales
9.2.3. Third-party Distributors
Chapter 10. Gene-to-Patient Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Gene-to-Patient Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.2.3. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.2.4. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.2.5. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.2.6. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3. Europe
10.3.1. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.3.3. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.3.4. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.3.5. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.3.6. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024- 2031
10.4.3. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.4.4. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Technology, 2024-2031
10.4.5. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.4.6. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
10.5. Latin America
10.5.1. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.5.3. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.5.4. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.5.5. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.5.6. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.6.3. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.6.4. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.6.5. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.6.6. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Illumina
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Thermo Fisher Scientific
11.2.3. Roche Diagnostics
11.2.4. Qiagen
11.2.5. BioRad Laboratories
11.2.6. Abbott Laboratories
11.2.7. PerkinElmer
11.2.8. Invitae
11.2.9. Myriad Genetics
11.2.10. Guardant Health
11.2.11. Foundation Medicine
11.2.12. Genomic Health
11.2.13. Agilent Technologies
11.2.14. Laboratory Corporation of America (LabCorp)
11.2.15. Exact Sciences
11.2.16. Genscript Biotech Corporation
11.2.17. CRISPR Therapeutics AG
11.2.18. Editas Medicine
11.2.19. Intellia Therapeutics Inc.
11.2.20. Beam Therapeutics Inc.
11.2.21. Caribou Biosciences Inc.
11.2.22. Lonza Group Ltd.
11.2.23. Other Market Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.